Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tolvaptan for Advanced Heart Failure and Hyponatremia
NCT02959411Phase 4Terminated
- Sponsor
- University of Calgary
- Start
- Oct 2016
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of tolvaptan in heart failure (HF) and hyponatremia, sponsored by University of Calgary. Primary endpoint: Change in body weight at 96 hours. Started Oct 2016; status: terminated.
02
Drugs
tolvaptan
03
Conditions
heart failure (HF)hyponatremia
Beyond the preview
Go deeper on NCT02959411.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02959411.